US Earnings Financial Results SEC Filings — August 11, 2026

11-08-2026

EQUATOR Beverage Co reported strong revenue growth of 14.2% YoY for Q2 2026 ($1.26M vs $1.10M) and 15.7% for H1 2026 ($2.22M vs $1.92M). Net income surged to $999,699 in Q2 (vs $153,056) and $1,175,814 in H1 (vs $237,090), driven by a large deferred tax benefit of $765,997. However, cash declined sharply to $73,757 from $219,457 at year-end 2025, and operating cash flow was only $55,935 despite higher net income, reflecting heavy inventory investment.

• · Gross profit margin improved to 56.6% in Q2 2026 (from 42.9% in Q2 2025) and 54.3% in H1 2026 (from 41.3% in H1 2025).
• · SG&A expenses rose 53.4% YoY in Q2 2026 and 65.4% in H1 2026, outpacing revenue growth.
• · Inventory increased 86.8% to $949,548 at June 30, 2026 from $508,301 at December 31, 2025.
• · Related party loans decreased to $160,000 at June 30, 2026 from $340,000 at December 31, 2025.
• · Deferred tax assets of $765,997 were recognized in H1 2026, contributing to the tax benefit.
• · Shares repurchased for cancellation totaled $21,635 in H1 2026, down from $60,000 in H1 2025.
• · The company issued $112,500 of restricted, non-trading common stock to directors and employees in H1 2026 (non-cash).

11-08-2026

Momentus Inc. filed its quarterly report (10-Q) for the period ended June 30, 2026, reporting a sharp decline in Q2 2026 service revenue to $25,000 from $191,000 in Q2 2025, while six-month revenue surged to $3.24 million from $513,000 due to hosted payload services. Net loss widened to $8.27 million in Q2 2026 from $6.45 million a year ago, and operating expenses more than doubled; however, the company dramatically improved its balance sheet, raising $94.84 million in net cash from financing activities and boosting cash and equivalents from $12.8 million to $107.6 million, while eliminating all preferred stock and loan payable.

• · Gross profit for the six months ended June 30, 2026 was $1.84M vs $511k in 2025, a 260% increase.
• · R&D expenses for Q2 2026 doubled to $4.23M from $2.19M a year earlier.
• · SG&A expenses remained relatively flat at $3.90M in Q2 2026 vs $3.94M in Q2 2025.
• · Total stockholders' equity surged from $17.14M at Dec 31, 2025 to $114.26M at June 30, 2026.
• · Net cash used in operating activities increased to $14.88M in the first half of 2026 from $7.42M in 2025.
• · Revenue breakdown: Hosted payload services contributed $1.64M year-to-date; engineering project services $1.60M.
• · Basic and diluted net loss per share improved to $(0.70) in Q2 2026 from $(22.03) in Q2 2025 due to a massive increase in weighted average shares outstanding (11.89M vs 292,791).

11-08-2026

Inhibikase Therapeutics reported a net loss of $19.6M for Q2 2026, widening from $9.9M in Q2 2025, driven by a surge in R&D expenses to $13.4M (up 154% YoY). Total cash and marketable securities fell sharply to $159.0M from $178.8M at year-end 2025, while operating cash burn more than doubled to $24.5M in the first half of 2026. The company's accumulated deficit grew to $178.7M.

• · Net loss per share (basic and diluted) was $0.11 for Q2 2026, unchanged from Q2 2025.
• · Weighted-average shares outstanding surged to 174.6M in Q2 2026 from 90.0M in Q2 2025, reflecting significant equity issuances.
• · Stock-based compensation expense was $10.9M for H1 2026, up from $6.3M in H1 2025.
• · The company held $127.8M in marketable securities (primarily U.S. Treasury obligations) as of June 30, 2026, up from $39.5M at year-end 2025.
• · Accrued research and development expenses jumped to $6.2M as of June 30, 2026 from $0.6M at December 31, 2025.
• · Contingent consideration liability was fully settled during H1 2026, with a $2.7M non-cash settlement.
• · Cash used in investing activities was $86.4M in H1 2026, driven by net purchases of marketable securities, compared to $30.9M provided in H1 2025.
• · Cash provided by financing activities was $2.9M in H1 2026, primarily from issuance of common stock, pre-funded warrants and warrants.

11-08-2026

Hour Loop, Inc. filed its 10-Q for the quarter ended June 30, 2026, reporting a 25.2% YoY increase in revenue to $33.9M for Q2, driven by 23.9% growth in the first half. However, net income for Q2 declined 10.6% YoY to $1.05M, and operating income fell 20.8% to $1.28M due to disproportionate growth in selling and marketing expenses (+23.9%) and cost of revenues (+37.7%). Cash flows remained negative, with cash used in operations of $3.56M in H1 2026, compared to $0.93M in the prior-year period, and cash at period-end was only $0.99M, though up from $0.33M a year ago.

• · Basic and diluted earnings per common share for Q2 2026 were $0.03, down from $0.04 in Q2 2025.
• · The company had $985,404 in cash at period-end, compared to $325,354 a year ago, but also had a negative cash flow from operations of $3.56M in H1 2026 (versus -$0.93M in H1 2025).
• · Inventory increased by 14% to $20.85M from $18.30M at December 31, 2025, while the inventory allowance decreased to $370,981 from $447,841.
• · Accounts receivable swung from a positive $1.17M in H1 2025 to a negative $2.47M in H1 2026, a major driver of the cash burn.
• · Stock-based compensation for H1 2026 was $29,999, essentially flat with $30,001 in the prior period.
• · The company received $1.63M from related parties during H1 2026, offset by $0.88M in repayments, compared to net payments of $0.84M in H1 2025.
• · Foreign currency translation adjustments were a loss of $13,657 in H1 2026 versus a gain of $141,403 in H1 2025.

11-08-2026

Tron Inc. reported a net income of $2.87M for Q2 2026 (up 95.3% YoY) and $24.5M for H1 2026 (up 2,883% YoY), driven primarily by large unrealized gains on digital asset investments and staking income. However, operating losses continued at $535,776 in Q2 and $1.13M in H1, while cash flow from operations was negative $959,762. The company also saw massive share dilution, with basic weighted average shares increasing from 21.6M to 470.2M YoY.

• · Total assets increased 21.2% from $211.4M to $256.2M, driven by a $35.7M increase in digital asset investments.
• · Total liabilities more than tripled from $1.12M to $3.39M, primarily due to a $2.25M deferred tax liability.
• · Shareholders' equity grew 20.2% from $210.3M to $252.8M, largely from net income and additional paid-in capital.
• · Inventory decreased 32.0% from $704,171 to $478,867.
• · Accounts receivable increased 56.0% from $671,779 to $1,047,995.
• · Prepayment for Digital Asset Purchases from an Affiliate was $10.05M as of June 30, 2026 (none at Dec 31, 2025).
• · The company issued 200 million common shares to Bravemorning Ltd upon conversion of Series B Preferred stock in Q2 2026.
• · Net cash used in operating activities worsened to -$959,762 in H1 2026 from -$165,653 in H1 2025.
• · No cash was raised from financing activities in H1 2026, compared to $4.11M in H1 2025.
• · The company purchased $7.95M of TRX tokens using USDT stablecoins in H1 2026.
• · Fair value of sTRX tokens increased from $198.1M to $229.7M, driven by unrealized gains and staking income.

11-08-2026

Brookfield Oaktree Holdings, LLC reported a strong turnaround in Q2 2026, with net income attributable to the company surging to $55.9M from $21.6M in Q2 2025, driven by a sharp swing in net realized and unrealized gains on consolidated fund investments. However, total revenues declined 24.7% YoY to $91.2M, and the company declared no Class A distributions in 2026 versus $0.83 per unit in Q2 2025, reflecting a cautious capital allocation stance.

• · Total assets increased to $7.07B as of June 30, 2026 from $6.80B at December 31, 2025.
• · Cash and cash-equivalents (parent) rose to $11.6M from $6.8M at year-end 2025.
• · Corporate investments decreased to $1.15B from $1.43B, partly due to the distribution of OCG NTR Holdings equity.
• · Debt obligations of consolidated funds increased to $1.50B from $1.32B.
• · Non-controlling redeemable interests in consolidated funds rose to $3.30B from $3.07B.
• · Paid-in capital dropped to $1.53B from $1.78B, reflecting the $317.4M non-cash distribution.
• · Retained earnings improved to $116.9M from $76.4M at year-end 2025.
• · For the six months ended June 30, 2026, net cash used in operating activities was $164.5M vs $540.0M provided in the prior year period.
• · Net income per Class A unit (basic and diluted) was $0.41 for Q2 2026 vs $0.12 for Q2 2025.

11-08-2026

Rithm Acquisition Corp. filed its 10-Q for the quarter ended June 30, 2026, reporting net income of $2.04M for the quarter and $6.24M for the nine-month period. The company's cash held in trust increased to $242.89M from $235.99M at fiscal year-end, driven by interest income. However, operating cash flow remained negative at -$542k, and cash on hand fell sharply from $551k to just $8.8k, as the company continues to search for a business combination target.

• · Trust account per-share redemption value rose to $10.56 as of June 30, 2026, from $10.26 at September 30, 2025.
• · Accumulated deficit increased to ($7,889,542) as of June 30, 2026, from ($7,220,746) at September 30, 2025.
• · No investing or financing activities occurred in the nine months ended June 30, 2026; all prior-period activity related to the IPO in 2025.
• · Interest earned on trust account was $2.24M for Q3 FY26 vs $2.56M for Q3 FY25, a decrease of 12.5%.
• · Weighted average shares outstanding for Class A ordinary shares remained constant at 23,660,000 across all periods.
• · Basic and diluted net income per share for both share classes was $0.07 for Q3 FY26, down from $0.08 in Q3 FY25.

11-08-2026

Eastern Co reported a mixed Q2 FY26 (quarter ended July 4, 2026). Net sales declined 11.9% YoY to $61.8M, and gross margin fell 22.1% to $12.8M, reflecting lower revenue. However, net income from continuing operations surged 177.6% to $5.6M, driven by a $6.5M bargain purchase gain from an acquisition completed on June 1, 2026. Operating profit dropped 47.2% to $1.7M, highlighting underlying operational weakness despite the one-time gain.

• · The company completed an acquisition on June 1, 2026 for $7.9M, acquiring net assets valued at $14.4M, resulting in a $6.5M bargain purchase gain.
• · The acquired business contributed $1.7M in net sales but a $123.6K operating loss for the period from acquisition to July 4, 2026.
• · Cash and cash equivalents more than doubled to $15.1M from $7.4M at the start of the fiscal year, driven by strong operating cash flow of $12.0M in H1 FY26 vs $1.9M in H1 FY25.
• · Long-term debt increased to $41.7M from $33.9M at year-start, reflecting $8.0M in new borrowings.
• · The company repurchased 40,649 treasury shares for $827.9K during H1 FY26, compared to 81,549 shares for $2.1M in H1 FY25.
• · Dividends remained flat at $0.11 per share quarterly ($0.22 per share for H1).

11-08-2026

WRAP TECHNOLOGIES, INC. reported a net loss of $2.257M for Q2 2026, improved from a $3.727M loss in Q2 2025, driven by a surge in product sales to $1.747M (from $50K) and a 103% increase in total revenues to $2.052M. However, technology-enabled services revenue fell 68% to $305K, and selling, general and administrative expenses rose 15% to $3.644M. The company raised $5M via a private placement in Q1 2026, boosting cash to $4.781M, but the accumulated deficit widened to $123.527M.

• · Net loss per share improved to $(0.04) in Q2 2026 from $(0.07) in Q2 2025.
• · Weighted average common shares outstanding increased to 55.73M in Q2 2026 from 50.61M in Q2 2025.
• · Share-based compensation expense was $3.403M in H1 2026 vs $2.435M in H1 2025.
• · Net cash used in operating activities improved to $3.679M in H1 2026 from $5.009M in H1 2025.
• · The company had a $227K gain on lease termination in H1 2026.
• · Customer deposits increased to $98K at June 30, 2026 from $62K at December 31, 2025.
• · Deferred revenue decreased to $385K at June 30, 2026 from $422K at January 1, 2026.
• · Inventory obsolescence reserve was $494K at June 30, 2026 vs $516K at December 31, 2025.
• · Dividends on convertible preferred stock were $411K in H1 2026, settled with common stock.
• · The company issued 2.5M common shares and pre-funded warrants in a private placement for $5M in Q1 2026.

11-08-2026

Fortress Net Lease REIT reported strong growth for Q2 2026, with total revenue surging 101.6% YoY to $79.3M for the quarter and 107.4% YoY to $149.2M for the first half, driven by a rapidly expanding real estate portfolio (total assets up 15.7% to $3.77B since year-end). Net income attributable to shareholders rose 35.7% YoY to $8.5M in Q2, and comprehensive income nearly doubled to $11.3M. However, the company's accumulated deficit widened to ($131.5M) from ($83.9M) at year-end, and earnings per share declined from $0.06 to $0.05 in Q2 and from $0.12 to $0.08 year-to-date, reflecting significant share dilution as weighted-average shares outstanding increased 63.8% to 179,631.

• · Total assets grew 15.7% to $3.77B from $3.25B at year-end 2025, driven by $433.8M in gross common share issuances and portfolio growth.
• · Net gain on dispositions of real estate was $3.2M in Q2 2026 vs $0 in Q2 2025.
• · Distributions declared increased 78.3% to $61.8M in H1 2026 from $34.7M in H1 2025, with the gross per-share distribution rising to $0.4335 from $0.3615.
• · Interest expense more than doubled, rising 167% in Q2 and 186% in H1, reflecting higher debt levels (revolving credit facility of $1.01B and term loans of $807.6M).
• · Other comprehensive income swung to a gain of $4.1M in H1 2026 from a loss of ($1.0M) in H1 2025, driven by a $4.5M increase in fair value of interest rate swaps.
• · Cash and cash equivalents surged to $41.8M from $4.0M at year-end, and restricted cash rose to $105.6M from $43.9M.

11-08-2026

Cambridge Acquisition Corp. (CAQ) filed its 10-Q for the quarter ended June 30, 2026, reporting net income of $2.17M for Q2 2026 and $2.68M for the first half of 2026, driven by $2.42M in interest earned on trust account investments. The company completed its IPO during the period, raising $230M in gross proceeds from the sale of 23 million units at $10 each, and also issued 495,500 private placement units for $4.96M. However, operating expenses totaled $504K for the six months, and the company ended the period with an accumulated deficit of $7.31M, reflecting the costs of the IPO and ongoing operations.

• · The company had no revenue and incurred $504,136 in formation, general and administrative costs for the six months ended June 30, 2026.
• · Interest earned on trust account investments was $2,420,956 for Q2 and $3,182,130 for the six months.
• · Total liabilities as of June 30, 2026 were $8,331,100, up from $107,784 at year-end 2025, primarily due to $8.05M deferred fee and $150K deferred consulting fees.
• · Shareholders' deficit was $(7,312,816) as of June 30, 2026, compared to $(38,178) at December 31, 2025.
• · Net cash used in operating activities was $356,816 for the six months.
• · The company had $866,504 in cash outside the trust account as of June 30, 2026.

11-08-2026

Karman Holdings Inc. reported strong revenue growth for the three and six months ended June 30, 2026, with revenue increasing 58.2% YoY to $182.1M in Q2 and 54.8% YoY to $333.3M in H1. Net income surged to $14.0M in Q2 (vs. $6.8M) and $21.8M in H1 (vs. $2.0M), driven by acquisitions and higher gross margins. However, operating cash flow remained negative at -$3.0M for H1 2026, though improved from -$31.0M in the prior year, and the company's debt load increased significantly with total liabilities rising to $1.02B from $721.4M at year-end 2025.

• · Gross margin improved to 43.0% in Q2 2026 from 40.8% in Q2 2025, and to 42.6% in H1 2026 from 40.2% in H1 2025.
• · Interest expense increased to $15.3M in Q2 2026 from $11.9M in Q2 2025, reflecting higher debt levels.
• · The company issued 135,000 shares of common stock in connection with the acquisition of Seemann Composites and Materials Sciences in Q1 2026.
• · Goodwill increased to $498.1M as of June 30, 2026 from $352.5M at December 31, 2025, primarily due to acquisitions.
• · Net cash used in operating activities improved to -$3.0M in H1 2026 from -$31.0M in H1 2025.
• · Capital expenditures increased to $21.9M in H1 2026 from $8.7M in H1 2025.

11-08-2026

908 Devices Inc. (MASS) reported Q2 FY2026 revenue of $16.1M (+23.3% YoY), driven by strong device sales growth of 33.1% to $11.0M. However, the company remains unprofitable, posting a net loss of $11.9M ($0.32/share) vs. a net loss of $13.3M ($0.37/share) in Q2 2025. The net cash burn and acquisition of NIRLAB (263,472 shares issued, ~$1.7M fair value) increased contingent consideration by $12.8M to $33.8M total, underscoring ongoing cash and profitability challenges.

• · Operating cash flow was positive $4.4M in H1 2026 — a significant improvement from negative $20.8M in H1 2025.
• · Contingent consideration ballooned to $33.8M total (current + non-current) at June 30, 2026, driven by the NIRLAB acquisition.
• · Net loss per share from continuing operations was $0.64 in H1 2026, unchanged YoY on a basic/diluted basis.
• · Goodwill of $11.1M and intangible assets of $45.1M were recognized following the NIRLAB acquisition, compared to zero goodwill and $36.4M intangibles at Dec 31, 2025.
• · Revenue from handheld product/service segment grew 23.4% YoY (Q2), while program product/service revenue declined 16.7% YoY (Q2).
• · Interest income declined 21.6% to $0.9M in Q2 2026 from $1.2M in Q2 2025, reflecting lower cash balances.
• · Income from transition services agreement was $1.2M in Q2 2025 vs. $0 in Q2 2026 after the Desktop Portfolio sale.

11-08-2026

Scientist Home Future Health Ltd (SHFH) reported a net loss of $199,924 for the six months ended June 30, 2026, a dramatic increase from a net loss of $31,154 in the prior year period. While retail trading revenue surged 247% to $265,156, selling, general and administrative expenses skyrocketed 347% to $288,101, far outpacing revenue growth. The company's cash position collapsed from $68,888 at year-end 2025 to just $9,047, and stockholders' equity turned deeply negative at ($86,324), indicating severe financial distress.

• · Service revenue was $1,425 for Q2 2026 and $7,903 for the six months, compared to $0 in both prior-year periods.
• · Gross profit for the six months was $88,177, up from $33,228 in the prior year, a 165% increase.
• · Depreciation expense was $7,450 for the six months ended June 30, 2026, versus $0 in the prior year.
• · Amortization of operating lease right-of-use assets was $36,867 for the six months, versus $0 in the prior year.
• · Net cash used in operating activities was $84,656 for the six months, compared to $10,126 in the prior year.
• · Net cash provided by financing activities was $25,105 for the six months, down from $102,959 in the prior year.
• · The company adopted ASC Topic 842 (leases) in 2026, recognizing $400,739 in right-of-use assets and lease obligations.
• · Total liabilities exceeded total assets by $86,324 as of June 30, 2026, resulting in negative stockholders' equity.
• · Amounts due to related parties and a director increased significantly, indicating reliance on related-party financing.

11-08-2026

DarioHealth Corp. reported a net loss of $7.9M for Q2 2026 and $16.2M for H1 2026, narrowing from $13.0M and $22.2M in the prior-year periods, respectively. Total revenues declined 3.6% YoY in Q2 to $5.2M and 11.2% YoY in H1 to $10.8M, driven by a sharp drop in services revenue (-29.4% in Q2, -36.6% in H1), partially offset by strong growth in consumer hardware revenue (+51.8% in Q2, +49.2% in H1). Operating expenses fell across all categories, and gross profit improved to $3.2M (61.7% margin) in Q2 from $3.0M (55.2% margin) a year ago. Cash and cash equivalents declined sharply to $6.6M as of June 30, 2026 from $21.8M at year-end 2025, reflecting ongoing cash burn.

• · Net cash used in operating activities was $12.1M in H1 2026, slightly improved from $12.7M in H1 2025.
• · Interest expenses on long-term loan were $1.1M in Q2 2026 and $2.3M in H1 2026, compared to zero in the prior-year periods (no loan existed then).
• · Total assets decreased 12.3% from $110.1M at Dec 31, 2025 to $96.6M at Jun 30, 2026.
• · Accumulated deficit grew to $468.3M as of Jun 30, 2026 from $452.1M at Dec 31, 2025.
• · The company had a long-term loan of $31.1M as of Jun 30, 2026, up slightly from $30.7M at Dec 31, 2025.
• · Warrant liability decreased sharply from $1.5M at Dec 31, 2025 to just $15K at Jun 30, 2026.
• · Stock-based compensation was $2.1M in H1 2026, down from $4.4M in H1 2025.
• · The company is evaluating the impact of new FASB accounting standard ASU 2024-03 on future disclosures.

11-08-2026

GPO Plus, Inc. (GPOX) filed its 10-K annual report for the fiscal year ended April 30, 2026, reporting a 16% increase in revenue to $5.5M and a 25% improvement in gross profit to $1.4M. However, the company remains unprofitable with a net loss of $2.4M, though this represents a 44% reduction from the prior year's $4.3M loss. The company's working capital deficiency worsened to $(6.6M) from $(5.6M), and cash used in operations increased to $1.4M, highlighting ongoing liquidity challenges.

• · Revenue growth was driven by wholesale markup, manufacturing, and delivery fees.
• · Operating expenses decreased 19% YoY to $3.5M, contributing to the reduced net loss.
• · Cash used in operating activities increased 35% to $1.4M, while financing activities provided $1.1M.
• · The company's cash balance decreased by $328.7K during the year, compared to an increase of $266.8K in the prior year.
• · Estimated total cash requirements going forward are $3.7M, with the largest components being G&A ($1.9M) and marketing ($700K).
• · The audit addressed debt accounting, including promissory note agreements, modifications, conversions, and related disclosures.

11-08-2026

Alamar Biosciences reported strong revenue growth in Q2 2026, with total revenue of $29.4M, up 82% YoY, driven by product revenue of $23.3M (+93%) and services revenue of $6.2M (+49%). However, the company's net loss widened to $13.2M in Q2 2026 from $7.0M in Q2 2025, and operating expenses increased significantly, particularly SG&A which more than doubled. The company completed its IPO during the quarter, raising net proceeds of $204.5M, and converted all convertible preferred stock and notes to common stock, strengthening its balance sheet.

• · IPO completed during Q2 2026, issuing 12,937,500 shares at net proceeds of $204.5M.
• · Convertible preferred stock and convertible notes converted to common stock, eliminating preferred stock and reducing debt.
• · Total assets increased from $140.0M to $391.0M, primarily due to IPO proceeds.
• · Accumulated deficit increased to $203.3M from $168.8M.
• · Operating cash flow used in operations was $31.7M for H1 2026, compared to $25.0M in H1 2025.
• · Inventory increased to $45.4M from $38.5M, reflecting investment in growth.
• · Accounts receivable increased to $20.3M from $12.8M, indicating higher sales.
• · SG&A expenses more than doubled in Q2 2026, reflecting public company costs and expansion.

11-08-2026

Cohen Circle Acquisition Corp. II (CCIIU) reported a net income of $1,976,256 for Q2 2026 and $3,841,889 for the first half of 2026, a significant turnaround from net losses of $34,148 and $39,568 in the same periods of 2025. The improvement was driven by $2,300,625 and $4,566,128 in interest earned on marketable securities held in the Trust Account for the three and six months ended June 30, 2026, respectively, compared to zero interest income in the prior year. However, operating losses widened to $324,369 (Q2) and $724,239 (H1) from $34,148 and $39,568 in the prior-year periods, and cash decreased 33.8% to $1,227,320 from $1,852,928 at year-end 2025.

• · Operating loss (G&A) increased 850% YoY in Q2 2026 to $324,369 from $34,148.
• · Operating loss (G&A) increased 1,730% YoY in H1 2026 to $724,239 from $39,568.
• · Cash decreased 33.8% to $1,227,320 from $1,852,928 at year-end 2025.
• · Accumulated deficit grew 8.2% to $9,563,591 from $8,839,352 at year-end 2025.
• · Net cash used in operating activities was $625,608 in H1 2026 vs. $0 in H1 2025.
• · Trust Account balance increased 1.8% to $262,216,441 from $257,650,313 at year-end 2025, driven by interest income.
• · Class A ordinary shares subject to possible redemption: 25,300,000 shares at $10.36 per share as of June 30, 2026 (vs. $10.18 at Dec 31, 2025).

11-08-2026

Insight Digital Partners II (DYORU), a SPAC, reported net income of $1,403,027 for Q2 2026 and $2,662,995 for H1 2026, driven by interest income on trust investments. However, operating expenses increased, and cash decreased significantly from $1,247,831 to $787,476. The company remains a shell company with no business operations, and its accumulated deficit widened to $6,084,054.

• · Class A ordinary shares subject to possible redemption: 17,250,000 shares at redemption value of $10.25 per share as of June 30, 2026.
• · Deferred underwriting fee of $6,900,000 remains unchanged.
• · Net cash used in operating activities for H1 2026 was $460,355.
• · The company is a shell company and an emerging growth company.
• · Warrants are exercisable at $11.50 per share.

11-08-2026

Exodus Movement, Inc. reported a net loss of $18.6M for Q2 2026 (vs. net income of $37.7M in Q2 2025) and a net loss of $50.8M for H1 2026 (vs. net income of $24.8M in H1 2025). Revenue was relatively flat in Q2 ($26.2M vs. $25.8M) but declined 20.8% for H1 ($49.0M vs. $61.8M). The company completed an acquisition in H1 2026, adding $342.3M in cash and $97.4M in goodwill, while total assets more than doubled to $596.7M. However, stockholders' equity fell from $247.4M to $201.0M due to the net losses.

• · General and administrative expenses surged to $44.7M in Q2 2026 from $18.8M in Q2 2025, a 137.6% increase.
• · Loss on digital assets, net was $7.0M in Q2 2026 vs. a gain of $52.5M in Q2 2025.
• · The company recognized a gain on debt extinguishment of $20.4M in Q2 2026.
• · Cash used in operating activities was $52.1M in H1 2026 vs. $11.4M in H1 2025.
• · Cash and cash equivalents and restricted cash totaled $355.1M as of June 30, 2026, up from $4.9M at the start of the period.
• · The acquisition added $48.9M in identifiable intangible assets (tradename, customer relationships, developed technology, licenses) and $97.4M in goodwill.
• · Customer deposit liabilities of $331.5M were recorded as of June 30, 2026, compared to $0 at year-end 2025.
• · Loans receivable, net dropped to $0 from $80.6M, settled as part of acquisition consideration.
• · Deferred tax assets increased to $5.7M from $13K, while deferred tax liabilities decreased to $5.3M from $12.0M.
• · Accumulated other comprehensive loss widened to $(4.3M) from $(2.1M).

11-08-2026

Black Spade Acquisition III Co filed its Form 10-Q for the quarter ended June 30, 2026, reporting net income of $848,429 for Q2 2026 and $1,935,638 for the first half of 2026, driven by interest earned on cash held in the Trust Account. The company completed its IPO during the period, placing $172.5 million in the Trust Account, and holds $175.5 million in trust as of June 30, 2026. However, the company continues to report an accumulated deficit of ($6.93 million) and negative operating cash flow of ($466,324) for the six months.

• · Net cash used in operating activities for H1 2026 was ($466,324).
• · The deferred underwriting fee payable at June 30, 2026 was $6.9 million.
• · Accretion for Class A ordinary shares to redemption amount totaled $13.9 million in Q1 2026 and $1.6 million in Q2 2026.
• · There were no comparable prior-period figures provided as the company was not operational before the IPO.

11-08-2026

Dominari Holdings Inc. reported a net loss attributable to common stockholders of $5.4M for Q2 2026, compared to net income of $16.6M in Q2 2025, driven by a sharp decline in underwriting revenue and a swing to losses on investments. Total revenue fell 57% YoY to $16.8M, while operating expenses dropped 67% to $17.9M, but the company still posted an operating loss of $1.1M versus a $14.9M loss a year ago. For the first half of 2026, the net loss widened to $62.8M from $15.9M in H1 2025, with cash and cash equivalents declining to $25.0M from $34.0M at year-end 2025.

• · Cash used in operating activities was $38.8M in H1 2026 vs cash provided of $0.9M in H1 2025.
• · Cash provided by investing activities was $45.0M in H1 2026 vs cash used of $4.3M in H1 2025, driven by net sales of marketable securities and securities owned.
• · Cash used in financing activities was $15.1M in H1 2026 vs cash provided of $8.8M in H1 2025, primarily due to $19.0M in dividends paid.
• · Income taxes payable surged to $15.6M as of June 30, 2026 from $7.3M at December 31, 2025.
• · Non-cash underwriting revenues were $10.1M in H1 2026 vs $3.0M in H1 2025.
• · Stock-based compensation – employees was $19.7M in H1 2026 vs $54.8M in H1 2025, a 64% decline.
• · Change in carrying value of investments resulted in a $1.4M loss in H1 2026 vs a $32.0M gain in H1 2025.
• · Gain/loss on marketable securities swung to a $7.1M loss in H1 2026 from a $0.6M gain in H1 2025.
• · Advisory fees dropped to $0.1M in H1 2026 from $21.0M in H1 2025, a 99.5% decline.
• · Common shares outstanding increased by 51% to 24.2M from 16.1M at year-end 2025, primarily from warrant exercises and stock issuances.
• · Total liabilities decreased to $35.5M from $43.5M at year-end 2025, but income taxes payable increased by $8.3M.

11-08-2026

BioCrude Technologies USA, Inc. filed its 10-Q for the quarter ended June 30, 2026, reporting no revenue and a net loss of $27,561 for the three-month period, an improvement from a net loss of $47,041 in the same quarter of 2025. For the six-month period, the net loss narrowed to $62,855 from $105,687 year-over-year. However, the company's cash position declined to $1,238 from $1,946 at year-end 2025, and total assets fell to $7,849 from $10,983, while total liabilities rose slightly to $485,305 from $482,430, resulting in a stockholders' deficit of $477,456.

• · The company had no revenue in both the three-month and six-month periods ended June 30, 2026 and 2025.
• · General and administrative expenses decreased to $26,706 for Q2 2026 from $41,480 in Q2 2025, a 35.6% reduction.
• · Interest expense fell to $855 in Q2 2026 from $5,561 in Q2 2025.
• · Cash used in operating activities was $56,311 for the six months ended June 30, 2026, compared to $57,839 in the prior year period.
• · The company raised $29,313 from private placements and $15,020 from stock issued for cash during the six months ended June 30, 2026.
• · Property, plant and equipment net decreased to $6,611 at June 30, 2026 from $9,037 at December 31, 2025, due to depreciation.
• · Accumulated deficit grew to $9,743,747 at June 30, 2026 from $9,676,929 at December 31, 2025.
• · The company eliminated its non-controlling interest of $3,964 during Q2 2026.

11-08-2026

Daedalus Special Acquisition Corp. (DSAC) reported net income of $2.13M for Q2 2026 and $4.16M for the first half of 2026, driven entirely by interest income from its trust account. However, the company continues to generate operating losses ($120K in Q2, $393K in H1) and its cash balance declined 41% to $627K, highlighting the cash burn of a pre-business-combination SPAC. The accumulated deficit widened to $8.06M, and the company has no operating revenue.

• · The company has no operating revenue and relies entirely on trust account interest income for profitability.
• · Class A ordinary shares subject to possible redemption are carried at $10.20 per share as of June 30, 2026, up from $10.02 at year-end 2025.
• · 291,667 Class B ordinary shares were forfeited in Q1 2026 in connection with the expiration of the over-allotment option.
• · The over-allotment option liability of $77,000 was extinguished in H1 2026, generating a one-time gain.
• · Net cash used in operating activities was $425,645 for the six months ended June 30, 2026.
• · Total liabilities decreased slightly from $8.95M to $8.83M, primarily due to the elimination of the over-allotment option liability and payment of offering costs.
• · The company has a shareholders' deficit of $8.06M, indicating liabilities and redeemable shares exceed assets.

11-08-2026

Quantum Corp reported Q1 FY2027 revenue of $80.8M, up 25.7% YoY, driven by a 43.5% surge in product revenue, while service and subscription revenue was flat. However, the company posted a net loss of $155.3M, a sharp deterioration from a $17.2M loss a year ago, primarily due to non-cash charges of $129.7M from the fair value change of the convertible note and $16.3M from warrant liabilities, along with an $11.7M loss on debt extinguishment. The balance sheet improved with total stockholders' deficit narrowing to $27.8M from $198.9M, and cash more than tripled to $54.4M following a $94.6M private placement and conversion of the convertible note into equity.

• · Gross profit increased 39.7% YoY to $31.7M from $22.7M, with gross margin improving to 39.3% from 35.3%.
• · Operating expenses decreased 24.4% YoY to $26.7M from $35.3M, including a sharp reduction in restructuring charges to $0.02M from $2.4M.
• · Income from operations swung to a positive $5.0M from a loss of $12.6M in the prior year.
• · Interest expense fell 67.8% YoY to $2.1M from $6.5M.
• · Term debt was fully repaid, with $56.8M repaid during the quarter, and the convertible note was converted into equity, eliminating $90.0M of debt.
• · Warrant liabilities increased to $31.7M from $14.1M at the start of the quarter.
• · Deferred revenue grew to $115.1M from $114.7M at the start of the quarter, with service revenue comprising the majority.
• · Accounts receivable decreased to $66.7M from $69.7M sequentially, but increased from $48.4M a year ago.
• · Net cash provided by operating activities was $0.9M, a significant improvement from a use of $16.9M in the prior year.
• · Weighted average shares outstanding more than doubled to 21,988 (in thousands) from 9,187 a year ago.
• · The company issued 10,616 thousand shares in a private placement, raising $94.6M net.
• · Accumulated deficit widened to $1.20B from $1.04B at the start of the quarter.

11-08-2026

APS BDC, LLC filed its first quarterly report (10-Q) for the period ended June 30, 2026, covering operations since its inception on January 2, 2026. The company reported total investment income of $51,582 for the quarter and net investment income of $29,344, but recorded a net decrease in net assets resulting from operations of $12,105 due to $17,239 in unrealized depreciation on its investment portfolio. Total net assets stood at $1,429,334 with a net asset value per unit of $19.06 as of June 30, 2026.

• · The company commenced operations on January 2, 2026, making this its first reporting period.
• · Total operating expenses for the three months ended June 30, 2026 were $22,238, with interest and financing fees being the largest component at $7,683.
• · Net cash used in operating activities for the period from inception through June 30, 2026 was $409,728, driven primarily by investment purchases of $700,730.
• · The company had $583,500 in borrowings under its revolving credit facility as of June 30, 2026.
• · Unrealized depreciation on First Lien Loans was $19,962 for the period from inception through June 30, 2026, while Second Lien Loans saw $8,008 in unrealized depreciation.
• · The company received $1,416,625 in proceeds from in-kind contributions during the period from inception through June 30, 2026.

11-08-2026

Groove Botanicals Inc. reported a net loss of $21,171 for Q2 FY2026 (three months ended June 30, 2026), a significant improvement from a net loss of $38,170 in the same period last year, driven by a $7,147 other income and reduced legal and professional expenses. However, the company still has zero revenue and continues to rely on related-party advances to fund operations, with cash declining to $1,494 from $2,737 a year ago. Total liabilities exceed total assets, and the accumulated deficit widened to $35,630,757, indicating ongoing financial distress.

• · Net sales remain zero for both Q2 FY2026 and Q2 FY2025.
• · Other income of $7,147 was recognized in Q2 FY2026, compared to $0 in the prior year.
• · Dividends payable increased to $472,144 (non-related party) and $237,884 (related party) as of June 30, 2026.
• · Total liabilities of $1,546,562 far exceed total assets of $2,525, resulting in a stockholders' deficit of $1,544,037.
• · The company had no investing activities in either period.
• · Net cash used in operating activities improved to $14,187 from $19,786 year-over-year.
• · Cash decreased by $8 during Q2 FY2026, ending at $1,494.

11-08-2026

Venture Global, Inc. reported strong financial results for Q2 2026, with revenue surging 47.6% YoY to $4,578M and net income attributable to common stockholders more than tripling to $1,347M from $368M in Q2 2025. However, operating expenses also grew significantly, with cost of sales up 17.0% and operating and maintenance expense up 54.4% YoY. The company continues heavy capital spending ($6,900M in H1 2026) across multiple LNG projects in construction and development stages, while net cash from operations increased to $2,835M.

• · LNG revenue was $4,556M in Q2 2026 vs $3,080M in Q2 2025, and $9,131M in H1 2026 vs $5,960M in H1 2025.
• · Other revenue was $22M in Q2 2026 vs $21M in Q2 2025, and $46M in H1 2026 vs $35M in H1 2025.
• · Interest income declined 31.6% YoY in Q2 2026 to $26M from $38M.
• · Interest expense, net increased 57.7% YoY in Q2 2026 to $489M from $310M.
• · Gain on interest rate swaps was $124M in Q2 2026 vs a loss of $112M in Q2 2025.
• · Loss on financing transactions was $96M in Q2 2026 vs $63M in Q2 2025.
• · Total stockholders' equity increased to $8,572M at June 30, 2026 from $6,743M at December 31, 2025.
• · Non-controlling interests stood at $3,507M at June 30, 2026 vs $3,557M at December 31, 2025.
• · Dividends declared on common stock were $0.018 per share in both Q1 and Q2 2026.
• · Net cash from financing activities was $5,005M in H1 2026 vs $2,140M in H1 2025, driven by $11,630M in debt issuance and draws on credit facilities.
• · Restricted cash (current and noncurrent) totaled $1,470M at June 30, 2026 vs $1,070M at December 31, 2025.
• · The company has five projects in construction or development stages: Plaquemines (construction/commissioning), CP2 (construction), and Plaquemines Expansion, CP2 Expansion, CP3 (development).

11-08-2026

Firefly Neuroscience reported Q2 2026 revenue of $514K, up 72% YoY from $299K, and H1 2026 revenue of $999K, up 192% YoY from $342K. However, the company's net loss widened to $1.98M in Q2 2026 from $1.83M in Q2 2025, and operating expenses increased 17% to $2.23M. Cash position improved significantly to $9.23M from $2.75M at year-end 2025, driven by $10.1M in net proceeds from share sales.

• · Allowance for expected credit losses increased to $22K as of June 30, 2026 from $10K at December 31, 2025.
• · Inventory decreased to $44K as of June 30, 2026 from $108K at December 31, 2025.
• · Deferred revenue (current) decreased to $215K as of June 30, 2026 from $228K at December 31, 2025.
• · Goodwill remained unchanged at $5.175M.
• · The company had a deemed dividend on warrant inducement of $90K in H1 2026, compared to $4.41M in H1 2025.
• · Share-based compensation expense was $691K in H1 2026, up from $324K in H1 2025.
• · The company raised $10.13M in net proceeds from share sales in H1 2026, compared to $2.56M in H1 2025.
• · Proceeds from warrant exercise were $150K in H1 2026, down from $8.83M in H1 2025.
• · The company deconsolidated a subsidiary in Q2 2026, resulting in a $45K gain.
• · Net cash used in operating activities improved to $3.70M in H1 2026 from $4.90M in H1 2025.

11-08-2026

Verde Clean Fuels, Inc. reported a net loss of $1.94M for Q2 2026, improving from a $2.55M loss in Q2 2025, and a six-month net loss of $4.33M versus $5.25M in the prior year. Operating expenses decreased 22% year-over-year to $2.52M, driven by lower G&A costs. However, cash used in operations improved to $3.44M from $5.88M, and the company ended the period with $53.55M in cash, down from $62.16M at mid-2025.

• · Research and development expenses increased 13.8% YoY to $165K in Q2 2026 from $145K in Q2 2025.
• · Net cash used in operating activities improved to $3.44M for the six months ended June 30, 2026, from $5.88M in the prior year.
• · Capital expenditures decreased significantly to $459K in H1 2026 from $2.02M in H1 2025.
• · Accrued liabilities increased to $1.14M at June 30, 2026 from $906K at December 31, 2025.
• · Property, plant and equipment net decreased to $53K from $62K at year-end 2025.

11-08-2026

Blackstone Infrastructure Strategies (TE) L.P. reported a significant increase in net assets resulting from operations for the six months ended June 30, 2026, reaching $482.1 million compared to $71.4 million in the prior year period, driven by a large unrealized gain on investments of $569.0 million. However, the fund recorded a net investment loss of $64.6 million for the period, versus a net investment income of $14.5 million in the prior year, as total expenses more than quadrupled to $119.1 million. Total net assets grew to $5.6 billion as of June 30, 2026, up from $3.8 billion at year-end 2025, supported by strong capital inflows from unit issuances.

• · Interest income for six months ended June 30, 2026 was $44.0M, up from $24.2M in the prior year period.
• · Performance participation allocation expense for six months ended June 30, 2026 was $69.3M, up from $11.0M in the prior year period.
• · Management fees for six months ended June 30, 2026 were $30.6M, up from $10.7M in the prior year period (before waiver).
• · Interest expense for six months ended June 30, 2026 was $8.2M, up from $1.0M in the prior year period.
• · Net realized loss on investments, derivative instruments and translation of assets and liabilities in foreign currencies for six months ended June 30, 2026 was $2.3M, compared to a loss of $5.8M in the prior year period.
• · Net change in unrealized loss on translation of assets and liabilities in foreign currencies for six months ended June 30, 2026 was $19.6M, compared to a gain of $10.5M in the prior year period.
• · Redemptions payable at the fund level were $13.9M as of June 30, 2026, up from $1.2M at December 31, 2025.
• · Distributions payable at the fund level were $41.3M as of June 30, 2026, up from $30.5M at December 31, 2025.

11-08-2026

HireQuest, Inc. reported strong Q2 2026 results with net income surging 154% YoY to $2.7M, driven by a sharp reduction in SG&A expenses. However, total revenue for the first half of 2026 declined 3.2% YoY to $14.6M, and cash from operations fell 58% to $1.9M, partly due to a large increase in accounts receivable. The company also repurchased $2.4M of its own shares during the six-month period.

• · Franchise royalties for H1 2026 were $13.6M, down 4.2% from $14.2M in H1 2025.
• · Service revenue grew 12.6% in H1 2026 to $975K from $866K in H1 2025.
• · Accounts receivable surged to $48.9M at June 30, 2026 from $39.3M at December 31, 2025, a 24.4% increase.
• · The company made a $192K capital contribution to an unconsolidated affiliate during H1 2026.
• · A gain on divestiture of $248K was recorded in H1 2026.
• · The company cancelled 48,849 treasury shares during H1 2026.
• · Basic EPS from continuing operations improved to $0.31 for H1 2026 from $0.18 in H1 2025.
• · Loss from discontinued operations was $69K for H1 2026, compared to $85K in H1 2025.

11-08-2026

Ampco-Pittsburgh reported a return to profitability in Q2 2026 with net income attributable to shareholders of $1,489 thousand versus a net loss of $7,335 thousand in Q2 2025, driven by improved operating income and the absence of a prior-year severance charge. However, total net sales declined 9.0% year-over-year to $102,918 thousand, and cash and cash equivalents fell to $7,047 thousand from $10,703 thousand at year-end 2025. The company also recorded a deconsolidation charge of $875 thousand in the first half of 2026.

• · Operating income improved to $5,072 thousand in Q2 2026 from a loss of $3,078 thousand in Q2 2025.
• · Inventories increased to $113,774 thousand at June 30, 2026 from $104,431 thousand at December 31, 2025.
• · Total liabilities decreased to $442,568 thousand at June 30, 2026 from $447,392 thousand at December 31, 2025.
• · Net cash provided by operating activities was $1,933 thousand in H1 2026 versus net cash used of $7,614 thousand in H1 2025.
• · Capital expenditures increased to $9,134 thousand in H1 2026 from $3,661 thousand in H1 2025.
• · Asbestos liability (current and noncurrent) totaled $184,976 thousand at June 30, 2026, down from $198,332 thousand at December 31, 2025.

11-08-2026

Twenty One Capital, Inc. (XXI) reported a net loss of $413.5M for Q2 2026 and $1.27B for H1 2026, driven primarily by a $1.25B non-cash fair value decline in its Bitcoin holdings. Total assets fell 32% from $3.93B to $2.66B, while stockholders' equity dropped 37% from $3.44B to $2.18B. The company's cash position decreased 10% to $106.1M, and operating expenses surged to $10.7M in Q2 2026 from $0.4M in the prior-year period, reflecting the company's growth since its March 2025 inception.

• · The company's accumulated deficit grew from $263.5M at Dec 31, 2025 to $1.54B at Jun 30, 2026.
• · Convertible notes payable remained nearly flat at $484.5M.
• · Operating cash burn was $11.6M in H1 2026, with no financing cash inflows.
• · Stock-based compensation totaled $12.1M in H1 2026.
• · The company had 13.4M stock options outstanding with a weighted average exercise price of $14.32 and a remaining life of 3.67 years.
• · 89.1 million Class B shares were cancelled during Q2 2026.
• · The company's business is heavily dependent on the price of Bitcoin, which is accounted for at fair value with changes recognized in net income.

11-08-2026

IMMUNIC, INC. reported a six-month 2026 net loss of $66,687, compared with $52,293 in the prior-year period, while total operating expenses increased to $68,562 from $53,908. However, the company significantly strengthened its liquidity through a February 2026 private placement, ending June 30, 2026 with $155,098 of cash and cash equivalents versus $15,483 at December 31, 2025; operating cash use also increased to $48,299 from $46,385.

• · Total assets increased to $159169 at June 30, 2026 from $24052 at December 31, 2025.
• · Total stockholders' equity improved from a deficit of $6673 at December 31, 2025 to equity of $127581 at June 30, 2026.
• · Interest income increased to $2046 for the six months ended June 30, 2026 from $424 in the prior-year period.
• · Other income (expense), net declined to an expense of $171 from income of $1191 in the prior-year period.
• · The company reported a six-month foreign currency translation gain of $124 in 2026 versus a loss of $1684 in 2025.
• · Money market funds totaled $110082 at fair value as of June 30, 2026, all classified as Level 1.
• · The February 2026 private placement was recorded net of issuance costs of $12747.
• · The company had 13644467 common shares issued and outstanding at June 30, 2026, compared with 12038263 at December 31, 2025.

11-08-2026

Shattuck Labs, Inc. reported a net loss of $15.2M for Q2 2026, widening from $12.5M in Q2 2025, driven by increased R&D spending. The company raised significant capital through stock and warrant offerings, boosting cash and investments to $208.3M at June 30, 2026, up from $78.1M at year-end 2025. However, the company remains pre-revenue with no product sales, and its accumulated deficit grew to $460.4M.

• · Cash used in operating activities was $23.6M in H1 2026, up from $22.5M in H1 2025.
• · Stock-based compensation expense was $5.1M in H1 2026, up from $3.6M in H1 2025.
• · Total assets increased to $220.7M at June 30, 2026 from $91.0M at December 31, 2025, primarily due to capital raises.
• · Total stockholders' equity rose to $211.1M from $82.4M over the same period.
• · The company had no revenue in any period presented.

11-08-2026

Vestis Corp reported a strong turnaround in its fiscal Q3 2026, posting net income of $11.0M compared to a net loss of $0.7M in the same quarter last year. Revenue declined 1.8% YoY to $661.7M, but operating income surged 49.2% to $37.2M, driven by improved cost management. For the nine-month period, net income was $7.3M versus a net loss of $27.7M in the prior year, though revenue fell 1.9% to $1.98B.

• · Total assets decreased to $2.83B from $2.91B at fiscal year-end 2025.
• · Long-term borrowings were reduced to $1.09B from $1.16B.
• · The company generated $160.9M in cash from operations in the first nine months of FY26, compared to $33.3M in the prior year period.
• · Selling, general and administrative expenses declined 11.1% YoY in Q3 to $114.9M.
• · The company did not pay any dividends in FY26, compared to $13.8M in dividends paid in the prior year nine-month period.
• · Accumulated deficit improved to $39.6M from $46.9M at fiscal year-end 2025.

11-08-2026

Neuraxis, INC reported strong revenue growth for Q2 2026, with net sales more than doubling to $1.93M from $0.89M in Q2 2025, a 115.7% increase. However, the company's net loss widened to $2.09M from $1.69M in the prior year quarter, driven by significant increases in operating expenses. While cash and cash equivalents improved to $8.32M from $4.97M at year-end 2025, the company continues to operate at a loss with an accumulated deficit of $69.66M.

• · Selling expenses increased 61.3% YoY to $861,387 in Q2 2026 from $534,013 in Q2 2025.
• · Research and development expenses increased 138.1% YoY to $274,344 in Q2 2026 from $115,197 in Q2 2025.
• · General and administrative expenses increased 45.6% YoY to $2,645,103 in Q2 2026 from $1,816,091 in Q2 2025.
• · Stock-based compensation for H1 2026 was $969,237, up from $278,854 in H1 2025.
• · Net cash used in operating activities improved to $2.26M in H1 2026 from $3.07M in H1 2025.
• · The company raised $5.06M from issuance of common stock in H1 2026.
• · Accounts payable surged to $791,587 as of June 30, 2026 from $139,365 at December 31, 2025.
• · Basic and diluted loss per share improved to $(0.19) in Q2 2026 from $(0.22) in Q2 2025.
• · Basic and diluted loss per share improved to $(0.37) in H1 2026 from $(0.56) in H1 2025.

11-08-2026

Chicago Atlantic Real Estate Finance, Inc. (REFI) reported a decline in net income for Q2 2026, with net income of $7.5M ($0.35 per basic share) compared to $8.9M ($0.42 per basic share) in Q2 2025, a 15.8% decrease. For the first half of 2026, net income fell 34.9% to $12.3M from $18.9M in the prior year period, driven by a significant increase in the provision for credit losses ($4.4M vs $0.07M) and lower net interest income. Total assets grew to $461.7M from $424.9M at year-end 2025, but the company's accumulated deficit widened to $23.5M, and stockholders' equity declined to $301.6M from $307.8M.

• · The company's current expected credit loss (CECL) reserve more than doubled to $9.4M from $5.1M at year-end 2025, reflecting a sharp increase in the provision for credit losses.
• · Net cash provided by operating activities fell 13.3% to $12.2M in H1 2026 from $14.1M in H1 2025.
• · The company issued $40.6M in loans at fair value to a related party during H1 2026, with no comparable activity in the prior year period.
• · Dividends declared on common shares totaled $0.94 per share for H1 2026, unchanged from H1 2025, but total dividends paid to common shareholders decreased to $20.8M from $24.0M.
• · Interest expense increased 14.8% to $2.4M in Q2 2026 from $2.1M in Q2 2025, and rose 6.8% to $4.4M for H1 2026 from $4.1M in H1 2025.
• · The revolving loan balance nearly doubled to $91.1M from $49.1M at year-end 2025, driving a 36.7% increase in total liabilities.

11-08-2026

Xtant Medical Holdings reported a net loss of $9.4M for Q2 2026, compared to net income of $3.6M in Q2 2025, driven by a $5.0M write-off of a distribution agreement deposit and a sharp decline in total revenue. Total revenue fell 35% YoY to $23.0M, as license revenue dropped to zero (from $5.0M) and spinal implant revenue declined 49% to $5.7M. Orthobiologics revenue also decreased 10% to $17.4M. For the six-month period, the company swung to a net loss of $12.5M from net income of $3.6M, with total revenue down 36% to $43.9M. Operating cash flow was negative $9.4M versus positive $2.6M a year ago.

• · Gross profit margin declined to 57.9% in Q2 2026 from 68.6% in Q2 2025.
• · Total operating expenses increased 14% YoY to $22.5M in Q2 2026, primarily due to the $5.0M write-off.
• · Excluding the write-off, operating expenses decreased 11% YoY.
• · Cash used in operations was $9.4M in H1 2026 vs cash provided of $2.6M in H1 2025.
• · The company had $10.2M in cash and restricted cash at June 30, 2026, up from $7.0M a year earlier, but down from $17.3M at Dec 31, 2025.
• · Inventories increased to $33.3M at June 30, 2026 from $30.3M at Dec 31, 2025.
• · Stockholders' equity decreased to $40.0M at June 30, 2026 from $48.5M a year earlier.
• · Basic and diluted loss per share were both $(0.07) in Q2 2026 vs earnings of $0.03 and $0.02 respectively in Q2 2025.

11-08-2026

Aura Biosciences reported a net loss of $79.3M for the first half of 2026, widening from a $54.5M loss in the prior-year period, driven by a 44% increase in operating expenses to $82.9M. The company strengthened its balance sheet significantly through a follow-on offering, raising $280.8M in net proceeds, which boosted total assets to $348.1M from $169.4M at year-end 2025. However, the company also initiated a $39.1M stock buyback program, repurchasing 6.9M shares, and its accumulated deficit grew to $559.7M.

• · General and administrative expenses more than doubled, increasing 112.1% to $24.2M in H1 2026 from $11.4M in H1 2025.
• · Stock-based compensation expense surged 120.4% to $16.2M in H1 2026 from $7.3M in H1 2025.
• · Cash used in operating activities increased 41.4% to $62.4M in H1 2026 from $44.1M in H1 2025.
• · The company's cash, cash equivalents and restricted cash balance declined 36.5% year-over-year to $68.6M as of June 30, 2026, from $108.1M as of June 30, 2025.
• · A follow-on offering in Q2 2026 raised $259.4M from common stock and $21.4M from pre-funded warrants, net of issuance costs.
• · The company repurchased 6,922,870 shares of common stock for $39.1M, including transaction costs, during Q2 2026.
• · Net loss per share (basic and diluted) improved slightly to -$0.98 from -$1.01, due to a 50.2% increase in weighted average shares outstanding.
• · Research and development expenses increased 27.0% to $58.7M in H1 2026 from $46.2M in H1 2025.

11-08-2026

Intensity Therapeutics reported a net loss of $3.0M for Q2 2026, widening from $2.5M in Q2 2025, driven by increased R&D spending. For the first half of 2026, the net loss narrowed to $5.4M from $5.9M in the prior year period, helped by lower operating expenses. Cash and cash equivalents fell to $9.5M as of June 30, 2026, from $11.9M at year-end 2025, as the company used $4.2M in operations but raised $1.8M through ATM offerings.

• · Total operating expenses for Q2 2026 were $3.1M, up from $2.7M in Q2 2025, an increase of 14.0%.
• · Total operating expenses for H1 2026 were $5.6M, down from $6.1M in H1 2025, a decrease of 8.0%.
• · Interest income increased to $77K in Q2 2026 from $17K in Q2 2025.
• · Net cash used in operating activities improved to $4.2M in H1 2026 from $4.4M in H1 2025.
• · The company raised $1.8M net from ATM offerings in H1 2026, compared to $328K net in H1 2025.
• · No proceeds from public offerings in H1 2026, compared to $4.7M gross ($3.7M net) in H1 2025.
• · Stock-based compensation decreased to $774K in H1 2026 from $1.1M in H1 2025.
• · The company issued 37,749 shares to the CEO in lieu of a cash bonus valued at $231K.
• · Weighted average shares outstanding increased to 2.7M in Q2 2026 from 0.75M in Q2 2025, reflecting significant dilution.
• · Loss per share improved to ($1.11) in Q2 2026 from ($3.36) in Q2 2025 due to higher share count.
• · Accumulated deficit grew to $83.8M as of June 30, 2026 from $78.4M at December 31, 2025.
• · Total stockholders' equity decreased to $9.2M as of June 30, 2026 from $11.9M at December 31, 2025.
• · All outstanding stock options and warrants had zero intrinsic value as of June 30, 2026, indicating the stock price was below exercise prices.

11-08-2026

11-08-2026

Tango Therapeutics reported a net loss of $55.3M for Q2 2026, widening from $38.9M in Q2 2025, driven by a 35% increase in R&D expenses and a near-doubling of G&A costs. The company ended the quarter with $1.03B in current assets (up from $354M at year-end 2025) after raising $651M in a common stock offering, but collaboration revenue fell to zero from $3.2M a year ago. The accumulated deficit grew to $704M, and the company continues to have no approved products or product revenue.

• · The company raised $651.4M in net proceeds from a common stock offering in Q2 2026, significantly boosting its cash position.
• · Stock-based compensation expense was $16.9M in Q2 2026, up from $10.8M in Q1 2026.
• · Total liabilities decreased slightly to $49.3M as of June 30, 2026 from $52.5M at year-end 2025.
• · The company has no products approved for commercial sale and has never generated product revenue.
• · Management states existing cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months.

11-08-2026

Upstream Bio, Inc. reported a net loss of $39.7M for Q2 2026, slightly improved from $40.0M in Q2 2025, while the six-month net loss widened to $80.3M from $67.2M. Revenue from collaboration decreased 17.5% YoY in Q2 to $0.8M, though six-month revenue grew 20.2% to $1.8M. The company's cash and investments declined to $261.3M from $341.5M at year-end 2025, with operating cash burn of $83.5M in H1 2026.

• · Net loss per share (basic and diluted) was $(0.73) for Q2 2026 vs $(0.74) for Q2 2025, and $(1.47) for H1 2026 vs $(1.25) for H1 2025.
• · Stock-based compensation expense was $9.0M in H1 2026, up from $5.2M in H1 2025.
• · Cash used in operating activities was $83.5M in H1 2026 vs $80.4M in H1 2025.
• · Proceeds from at-the-market offering of common stock were $2.1M in H1 2026; no such proceeds in H1 2025.
• · Total assets decreased to $281.2M at June 30, 2026 from $353.8M at December 31, 2025.
• · Accumulated deficit increased to $414.5M from $334.2M at year-end 2025.
• · Fair value of cash equivalents and short-term investments totaled $260.7M at June 30, 2026, down from $340.8M at December 31, 2025.
• · Property and equipment, net, declined to $460 from $559 at year-end 2025.

11-08-2026

Zura Bio reported a net loss of $50.5M for H1 2026, up from $33.4M in H1 2025, driven by a doubling of R&D expenses to $35.5M as clinical programs for tibulizumab (SSc and HS) advanced. The company strengthened its balance sheet with a February 2026 equity offering, raising $134.6M net, boosting cash to $205.1M. However, operating cash burn widened to $39.8M from $27.1M, and the accumulated deficit grew to $275.1M.

• · R&D expenses for tibulizumab HS program more than doubled in H1 2026 ($9.4M vs $3.3M in H1 2025).
• · R&D expenses for tibulizumab SSc program increased 77% in H1 2026 ($7.4M vs $4.2M in H1 2025).
• · General and administrative expenses increased only 6.8% in H1 2026, with wages and benefits actually declining 13%.
• · The February 2026 equity offering included 21.2 million Class A ordinary shares and pre-funded warrants, raising $134.6M net.
• · Cash and cash equivalents increased 87.5% from December 31, 2025 to June 30, 2026.
• · Net loss per share widened from $0.36 to $0.42 in H1 2026.
• · The company had no revenue and expects to continue incurring losses as it advances its clinical pipeline.

11-08-2026

Sagimet Biosciences reported a net loss of $13.95M for Q2 2026 (ending June 30, 2026), compared to a net loss of $10.39M in Q2 2025, representing a 34.3% increase in losses. Revenue remained absent as the company is pre-commercial, with R&D expenses rising 59.2% to $11.54M from $7.25M year-over-year. However, the company strengthened its cash position significantly, ending the quarter with $165.9M in cash and cash equivalents versus $35.0M at year-end 2025, following a $175M equity offering in April 2026.

• · The company completed a public offering of 29,166,700 shares of Series A common stock in April 2026, raising net proceeds of approximately $163.9 million after issuance costs of $11.1 million.
• · Weighted-average shares outstanding increased from 32.2 million in Q2 2025 to 53.1 million in Q2 2026, reflecting the equity offering.
• · Accumulated deficit grew to $370.95 million as of June 30, 2026, from $346.35 million at year-end 2025.
• · Total comprehensive loss for Q2 2026 was $14.04 million, compared to $10.43 million in Q2 2025.
• · Cash used in operating activities improved to $19.71 million in H1 2026 from $23.64 million in H1 2025.
• · The company had no revenue and is pre-revenue, focused on clinical-stage development.

11-08-2026

C4 Therapeutics reported a net loss of $23.6M for Q2 2026, improving from a $26.0M loss in Q2 2025, while revenue from collaboration agreements rose slightly to $6.6M from $6.5M. Operating expenses decreased 5.4% year-over-year to $33.1M, driven by lower R&D spending. However, the company's accumulated deficit grew to $787.5M, and cash used in operations improved to $31.5M in H1 2026 from $45.3M in H1 2025, supported by a $33.5M at-the-market equity offering.

• · Stock-based compensation expense decreased to $5.7M in H1 2026 from $10.5M in H1 2025.
• · Net cash used in operating activities improved to $31.5M in H1 2026 from $45.3M in H1 2025.
• · The company raised $33.5M net from an at-the-market equity offering in Q2 2026.
• · Deferred revenue increased to $40.4M as of June 30, 2026 from $28.3M as of December 31, 2025.
• · Total stockholders' equity decreased to $247.3M as of June 30, 2026 from $256.6M as of December 31, 2025.
• · Weighted-average shares outstanding nearly doubled to 130.7M in Q2 2026 from 71.0M in Q2 2025 due to warrant exercises and equity offerings.

11-08-2026

LB Pharmaceuticals reported a net loss of $51.6M for Q2 2026, a significant increase from $4.9M in Q2 2025, driven by a surge in R&D spending to $44.1M (from $2.4M) as the company advanced its schizophrenia and bipolar depression programs. The company raised $100M in a private placement during H1 2026, boosting cash and marketable securities to $327.8M as of June 30, 2026, up from $295.2M at year-end 2025. However, operating expenses grew sharply, and the accumulated deficit widened to $200.2M, reflecting the company's heavy investment phase.

• · Net loss per share for Q2 2026 was $1.71, compared to $13.58 in Q2 2025, reflecting a significant increase in weighted average shares outstanding from 358,811 to 30,137,733.
• · The company issued 3,306,571 shares of common stock and pre-funded warrants in a private placement, raising $100M gross proceeds (net $93.8M after issuance costs).
• · Total liabilities increased from $11.6M at Dec 31, 2025 to $29.3M at Jun 30, 2026, driven by higher accrued expenses and operating lease liabilities.
• · Cash used in operating activities for H1 2026 was $60.9M, up from $13.7M in H1 2025.
• · The company had no revenue and continues to rely on funding to support operations.

11-08-2026

Barnwell Industries reported a net loss of $403,000 for Q3 FY2026, a significant improvement from a $1,553,000 loss in Q3 FY2025, driven by lower operating costs and a $376,000 equity income from affiliates. However, for the nine-month period, the net loss narrowed to $2,931,000 from $4,679,000, while oil and natural gas revenues declined 20.2% to $8,454,000. The company strengthened its balance sheet with a $4,381,000 stock issuance, boosting cash to $4,467,000, but accumulated deficit widened to $9,524,000.

• · General and administrative expenses decreased 24.6% YoY in Q3 to $1,409,000 and 12.5% for the nine months to $4,546,000.
• · Depletion, depreciation, and amortization fell 35.3% YoY in Q3 to $546,000 and 32.1% for the nine months to $1,699,000.
• · No impairment of assets was recorded in FY2026, compared to $200,000 in Q3 FY2025 and $865,000 for the nine months.
• · Equity in income of affiliates contributed $376,000 in Q3 and $714,000 for the nine months, versus nil in the prior year.
• · Cash used in operating activities from continuing operations was $3,099,000 for nine months FY2026, compared to $1,163,000 used in the prior period.
• · Capital expenditures for oil and natural gas were $269,000 for nine months FY2026, down from $2,954,000 in the prior year.
• · The company issued 884,093 shares of common stock, net of issuance costs, raising $1,016,000 in Q3 FY2026.
• · Discontinued operations (contract drilling) had no activity in FY2026; in FY2025 they contributed net earnings of $12,000.
• · Non-controlling interests reported net earnings of $37,000 in Q3 FY2026 versus a loss of $3,000 in Q3 FY2025.